Mendus – executive interview

Mendus is an immuno-oncology company specialising in the field of allogeneic dendritic cell biology. It has two clinical-stage assets, vididencel and ilixadencel, both of which are off-the-shelf cell-based vaccines, designed to improve survival outcomes for cancer patients. Mendus is developing the lead programme, vididencel, as a maintenance therapy for acute myeloid leukaemia (AML). The company recently presented encouraging long-term survival data from the ADVANCE II trial, a Phase II trial evaluating vididencel as a single-agent treatment for AML patients with measurable residual disease following chemotherapy. Preparations are underway for pivotal studies aimed at market registration of vididencel based in combination with oral azacitidine, currently the only approved AML maintenance treatment. Mendus aims to be pivotal-stage ready by H225.

In this video, we speak to Erik Manting, CEO of Mendus, focusing primarily on lead asset, vididencel. We discuss some of the key takeaways from Mendus’s updates at ASH 2024 in haematological cancers, its clinical plans and manufacturing capabilities as the AML programme approaches the pivotal stages of development, as well as vididencel’s potential in ovarian cancer. We also cover the key milestones that investors should watch out for as we move into 2025.